Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)

Table 1 Patient characteristics (N = 10) and responses

Patient ID No.	Sex/ Age (years)	ECOG PS	IELSG score*	Disease state	Previous therapy	Tumor location	R-B(O)AD cycles completed	Final response	PFS/OS (months)
1	F/68	2	5	Ref	HDMTX+ AraC	D; periventricular, basal ganglia	3	PD	1.8/7.3
2	F/55	2	4	Ref	HDMTX+ AraC	D; periventricular, corpus callosum	2	PD	2.5/6.8
3	M/75	1	4	Rel	HDMTX + WBRT; MPV-A	ND; L optic nerve	4	CR	21.7/> 21.7
4	M/42	2	3	Ref	HDMTX	D; basal ganglia	2	PD	1.6/9.1
5	M/78	2	3	Rel	HDMTX+ AraC	ND; L parietal	4	PR	6.9/> 6.9
6	F/55	2	4	Ref	HDMTX+ AraC	ND; L frontal, R temporal	3	PD	2.8/3.3
7	F/47	1	2	Ref	HDMTX+ AraC	D^t; L frontal, periventricular	1	PR	2.8/2.8
8	F/73	2	5	Rel	HDMTX+ AraC	ND; L frontal	4	PR	4.4/4.4
9	M/75	2	4	Ref	HDMTX+ AraC	ND^t; L frontal	2	SD	4.2/> 4.2
10	M/65	2	5	Ref	HDMTX	D^t; L frontal, basal ganglia	2	PR	3.9/3.9

Abbreviations: M, male; F, female; PS, performance status; Rel, relapsed; Ref, refractory; HDMTX, high dose methotrexate; AraC, cytarabine; WBRT, whole brain radiotherapy; MPV-A, methotrexate, vincristine, procarbazine, cytarabine; D, deep; ND, non-deep; L, left; R, right; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival
*IELSG risk = intermediate (IELSG score 2–3), high (IELSG score 4–5)
^tPatients with leptomeningeal involvement in recurrent disease

ISSN: 1471-2407